Angioplasty with sirolimus-coated balloons, as compared with uncoated balloons, reduced limb amputation and other adverse ...

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated, with fewer ...

Please provide your email address to receive an email when new articles are posted on . Researchers presented a new subanalysis of the STRIDE trial. Ozempic improved walking distance in patients with ...

Peripheral Artery Disease Awareness: What You Need to Know September is Peripheral Artery Disease (PAD) Awareness Month, and to help raise awareness, Dr. Carlos Rueda, a vascular surgeon with the ...

For femoropopliteal and BTK patients, the sirolimus balloon was associated with fewer limb events at 1 year than POBA.

WOMEN. WELL, THE DOCTOR I SPOKE WITH SAYS A BIG PROBLEM WITH VASCULAR DISEASE IS SOME OF THE SYMPTOMS, LIKE NOT HAVING A LOT OF HAIR ON YOUR SHIN OR HAVING SHINY SHINS CAN BE MISSED EARLY ON. VASCULAR ...

DOCTOR, BLACK WOMEN ARE MORE LIKELY TO DEVELOP PERIPHERAL ARTERY DISEASE, WHICH IS OTHERWISE KNOWN AS PAD. NOW, THESE CASES TEND TO START IN YOUNGER WOMEN, BUT IN BLACK WOMEN, IT PROGRESSES FASTER ...

Please provide your email address to receive an email when new articles are posted on . Ozempic improved walking distance in patients with diabetes and peripheral artery disease at 1 year. An ...

New clinical results highlight the need for inclusive approaches and comprehensive examinations of treatment options for peripheral artery disease (PAD), including endovascular therapy and ...

SAN ANTONIO — There are over 200,000 avoidable amputations every year in the U.S. Many occur with diabetes, but many of these amputations also come from a condition that many may have never heard of.

When most people think of atherosclerosis, coronary artery disease (CAD) and stroke come to mind, but a strong third player on the atherosclerotic landscape is peripheral artery disease (PAD). This ...